Company intelligence

IXHL

Incannex Healthcare Limited · NASDAQ · Healthcare

Price$3.29+0.92% · +$0.03

Market cap39.36MEquity value

P / E-4.8Trailing ratio

Volume84.05KLatest session

Market data

IXHL price chart

TradingView

Related signals

1 min delayed

Browse public IXHL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

IXHLMar 12, 2026-45.06% since signal

Incannex Healthcare Announces $10 Million Capital Raise to Fund Phase 2 Study

Incannex Healthcare is set to raise approximately $10 million from institutional investors through the sale of 2 million shares and accompanying warrants. This funding is pivotal for advancing the Phase 2 clinical trial of its lead candidate, IHL-42X, which targets obstructive sleep apnea, and it positions the company for further growth with anticipated Phase 3 studies starting in late 2027.

View signal analysis

IXHLJul 30, 2025-35.59% since signal

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

Incannex announced positive Phase 2 trial results for IHL-42X treatment. Significant AHI reductions achieved: 83% in high-dose, 79% in low-dose IHL-42X. Patient-reported outcomes show improvement in sleep-related impairments. IHL-42X well tolerated with mild or moderate side effects reported. IXHL stock rose 24.3% following the announcement.

View signal analysis

Research